SHIONOGI-B.V.
SHIONOGI B.V., the European subsidiary of SHIONOGI & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") and L. MOLTENI & C. DEI F.LLI ALITTI SOCIETÀ DI ESERCIZIO S.P.A. (Headquarters: Florence, Italy; Managing Director : Giuseppe Seghi Recli, hereafter “Molteni”) announced today that Shionogi and Molteni concluded a contract for the distribution and sale of RIZMOIC® (naldemedine) for the treatment of opioid-induced constipation (OIC) in adult patients previously treated with a laxative in the two key European markets, Italy and Poland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190521005648/en/
Shionogi has built a strong heritage in research-based medicine. The company’s research and development efforts target pain/central nervous system as one of its priority areas in the mid-term business plan. The company constantly strives to improve the quality of life of patients who suffer from pain or side effects of analgesics by bringing forth innovative drugs.
Molteni is a specialty leader in the field of opioid treatments in Europe and is committed to researching and developing novel solutions for the treatment of moderate to severe pain and addiction, to safeguard patients’ quality of life and care. According to this contract, Molteni will distribute and sell RIZMOIC® in Italy and Poland and Shionogi will co-promote the product in Italy with Molteni.
Dr. John Keller, Chief Executive Officer of Shionogi B.V., the subsidiary of Shionogi in Europe, said “This partnership marks another key milestone for the launch of RIZMOIC ® in Europe. By partnering with Molteni, we are combining our extensive knowledge of opioid pain management to ensure more patients experiencing OIC can have access to this important treatment option. The co-promotion of Shionogi and Molteni in Italy offers a synergic partnership to maximise the value of existing commercial structures”.
Molteni’s Managing Director, Giuseppe Seghi Recli, commented, “We are delighted to partner with Shionogi on such a promising new molecule for the treatment of OIC and we believe that the outstanding commitment shown by both parties since the beginning of our discussion will significantly contribute to raising a new patient’s awareness capable to tackle this disabling and under diagnosed pathology.”
On February 22, 2019, the European Commission (EC) granted the Marketing Authorization (MA) for RIZMOIC ® for the treatment of OIC in adult patients who have previously been treated with a laxative.1,2 RIZMOIC® is planned to be launched in Italy and Poland in 2020. RIZMOIC® was launched under the brand name Symproic® in Japan in June 2017, and in the United States in October 2017.3-5
Shionogi plans to initiate a clinical study of naldemedine in paediatric patients with OIC in the EU, in accordance with an agreed paediatric investigation plan, as well as a clinical study in adult patients with post-operative ileus.
END
References
1.
Release on February 22, 2019
Shionogi announces European Union
Marketing Authorisation for RIZMOIC®
(naldemedine) for the
treatment of opioid-induced constipation in adults previously treated
with a laxative
2.
SmPC, RIZMOIC®
, Shionogi,
Feb 2019. [online] Available at: https://www.ema.europa.eu/documents/product-information/rizmoic-epar-product-information_en.pdf
[Accessed 20 May 2019].
3.
Release on June 7, 2017
Opioid-Induced Constipation therapeutic
agent ‘Symproic®
(naldemedine) Tablets 0.2mg’ launched in
Japan
4.
Release on October 12, 2017
Shionogi Inc. and Purdue Pharma
L.P. Announce U.S. Availability of Symproic®
(naldemedine)
for the Treatment of Opioid-Induced Constipation in Adults with Chronic
Non-Cancer Pain
5.
Release on April 11, 2019
Shionogi Announces Licensing of
Symproic® (naldemedine) to BioDelivery Sciences International Inc.
6.
Sehgal N, et al. Chronic pain treatment with opioid analgesics benefits
versus harms of long-term therapy. Expert Rev Neurother.
2013;13:1201-1220.
7.
Camilleri M, et al. Emerging
treatments in neurogastroenterology: a multidisciplinary working group
consensus statement on opioid-induced constipation. Neurogastroenterol
Motil. 2014;26: 1386-1395.
8.
Coyne E, et al.
Opioid-Induced constipation among patients with chronic Noncancer pain
in the United States, Canada, Germany and the United Kingdom: Laxative
use, response and symptom burden over time. Pain. 2015;16:1551–1565.
9.
Hale M, et al. Naldemedine versus placebo for opioid-induced
constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase3,
double-blind, randomised, parallel-group trials. Lancet Gastroenterol
Hepatol. 2017. Published online May 30, 2017.
10.
Webster L, et al. Long term use of naldemedine in the treatment of
opioid-induced constipation in patients with chronic noncancer pain: a
randomized, double-blind, placebo-controlled phase 3 study. Pain. 2018.
Published online February 2018.
11.
Bowers B, et al. The
evolving role of long-term pharmacotherapy for opioid-induced
constipation in patients being treated for noncancer pain. Jour Pharm
Practice. 2017.
12.
Katakami N, et al. Randomized phase
III and extension studies: efficacy and impacts on quality of life of
naldemedine in subjects with opioid-induced constipation and cancer. Ann
Oncol. 2018. Published online Apr 18, 2018.
13.
Satomi
E, et al. Efficacy and tolerability of naldemedine in patient with
cancer and opioidinduced constipation: A pooled subgroup analysis of 2
randomised placebo-controlled studies. Ann Oncol. 2018. 29 (suppl 8).
View source version on businesswire.com: https://www.businesswire.com/news/home/20190521005648/en/
Contact:
Shionogi Europe Dr. Mark Hill, Shionogi mark.hill@shionogi.eu Mirjam Korn, Shionogi mirjam.korn@shionogi.eu Shionogi & Co., Ltd. Corporate Communications Department Telephone: +81-6-6209-7885 Molteni Italy Ufficio stampa – Chapter4 Tel. +39 -02 36795940 Elena Santoro - santoro@chapter4.it Flavia Testorio - testorio@chapter4.it
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ares Management Acquires Minority Stake in Plenitude for €2 Billion23.6.2025 07:35:00 CEST | Press release
Ares Management Corporation (“Ares”) (NYSE: ARES), a leading global alternative investment manager, announced today that Ares Alternative Credit funds (“Ares Alternative Credit”) have entered into a definitive agreement for the acquisition of a 20% stake in Plenitude, a leader in energy transition controlled by Eni, for approximately €2 billion. The consideration implies an enterprise value for Plenitude of over €12 billion. Completion of the transaction is subject to customary regulatory approvals. Plenitude operates in over 15 countries worldwide, integrating a business model that combines over 4 GW of renewable energy production, as well as retail and energy solutions. The company serves more than 10 million customers and manages an extensive network of 21,500 charging points for electric vehicles. “This transaction underscores the strength of the Ares platform, which leverages experience across its diversified businesses, including asset-based finance and renewables infrastructure,
DentalMonitoring Launches "Top Ortho Practice Award" to Recognize Data-Driven Excellence in Orthodontic Care20.6.2025 19:08:00 CEST | Press release
DentalMonitoring, the global leader in AI-powered remote monitoring for orthodontics, is proud to announce the launch of the Top Ortho Practice Award, the first-of-its-kind recognition program that celebrates top-performing orthodontic practices worldwide through objective, data-based analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250620540366/en/ Unlike traditional awards based on subjective nominations or popularity, the Top Ortho Practice Award is rooted in objective metrics derived from millions of patient scans and clinical interactions. Practices are selected based on exceptional outcomes in hygiene, compliance, and treatment effectiveness, using standardized benchmarks that reflect regional and global performance levels. The program identifies and celebrates practices that lead their territories in performance metrics derived from actual patient data, including hygiene, clinical techniques, and post-treatmen
SLB Announces Second-Quarter 2025 Results Conference Call20.6.2025 19:00:00 CEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 18, 2025 to discuss the results for the second quarter ending June 30, 2025. The conference call is scheduled to begin at 9:30 am U.S. Eastern time and a press release regarding the results will be issued at 7:00 am U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (833) 470-1428 within North America or +1 (404) 975-4839 outside of North America approximately 10 minutes prior to the start of the call and the access code is 719185. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/492107617 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 25, 2025, and can be accessed by dialing +1 (866) 813-9403 within North America or +1 (929)
TH Global Capital Named 'Boutique Investment Banking Firm of the Year' for the Third Year Running at the 16th Annual International M&A Awards20.6.2025 18:18:00 CEST | Press release
TH Global Capital, a global boutique investment banking firm with operations across 13 countries in the Americas, Europe, and Asia-Pacific, with a track record of closing transactions in 29 countries, has won four prestigious awards at the 16th Annual International M&A Awards, including ‘Boutique Investment Banking Firm of the Year’ for the third consecutive year. TH Global Capital’s awards include: Boutique Investment Banking Firm of the Year 2025 Corporate/Strategic Deal of the Year ($50MM-$100MM): For advising Cloobees, a Global Salesforce Summit Partner in Poland, on its strategic sale to New York headquartered Synechron. Regional Deal of the Year – Asia: For advising Brainvire, a leading global Digital Commerce and Digital Marketing agency in Asia, on its merger with Said Differently, a Falfurrias portfolio company in the US. M&A Deal of the Year ($50MM–$100MM): For advising Chamonix IT and Exposé, leading Australian companies in Digital Engineering and AI & Data Science respectiv
Kuwait Celebrates National Day at Expo 2025 Osaka with a Striking Showcase of Culture, Vision and Purpose20.6.2025 15:03:00 CEST | Press release
The State of Kuwait marked its National Day at Expo 2025 Osaka, Kansai, with a celebration that captivated audiences and strengthened the pavilion’s growing reputation as one of the most compelling destinations at the global event. The day’s activities brought together dignitaries, Expo visitors and international media in a vibrant tribute to Kuwait’s heritage, identity and forward-looking vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250620543251/en/ Kuwait celebrates National Day at Expo 2025 Osaka with a striking showcase of culture, vision and purpose (Photo: AETOSWire). The celebrations began with a parade featuring more than 100 participants, dressed in traditional attire and accompanied by music and movement. The procession drew large crowds across the Expo site, attracting attention for its energy, colour and cultural authenticity. The official ceremony took place at the National Day Hall within the Expo pre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom